Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BSF EnterpriseBSFAF Equity-to-Asset is 0.51 as of Mar. 2026, which is 44% below its 10-year median of 0.91. The stock has 3 warning signs investors should review. Among 1,414 Biotechnology companies, BSF Enterprise ranks worse than 65.91% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. BSF Enterprise's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $2.35 Mil. BSF Enterprise's Total Assets for the quarter that ended in Mar. 2026 was $4.62 Mil.
Therefore, BSF Enterprise's Equity to Asset Ratio for the quarter that ended in Mar. 2026 was 0.51.
The historical rank and industry rank for BSF Enterprise's Equity-to-Asset or its related term are showing as below:
BSFAF'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.3 Med: 0.91 Max: 0.97
Current: 0.51
During the past 7 years, the highest Equity to Asset Ratio of BSF Enterprise was 0.97. The lowest was 0.30. And the median was 0.91.
BSFAF's Equity-to-Asset is ranked worse than 65.91% of 1414
companies
in the Biotechnology industry
Industry Median: 0.68
vs BSFAF: 0.51
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
BSF Enterprise Equity-to-Asset Related Terms
BSF Enterprise Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for BSF Enterprise's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSFAF vs VRTX, REGN, MRNA: Equity-to-Asset Comparison
For the Biotechnology subindustry, BSF Enterprise's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BSF Enterprise Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BSF Enterprise's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where BSF Enterprise's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
BSF Enterprise's Equity to Asset Ratio for the fiscal year that ended in Sep. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSF Enterprise (BSFAF) has a Equity-to-Asset of 0.51 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on BSF Enterprise and its competitors. This is 44% below median its historical median of 0.91. Over the past decade, BSF Enterprise's Equity-to-Asset has ranged from 0.30 to 0.97. According to the industry distribution chart, BSF Enterprise ranks #932 out of 1414 companies in the Biotechnology industry, placing it in the top 65.9%.
Is BSF Enterprise's Equity-to-Asset too high?
BSF Enterprise's current Equity-to-Asset of 0.51 is 44% below median its 10-year median of 0.91. Over the past 10 years, this metric has ranged from a low of 0.30 to a high of 0.97. The Biotechnology industry median Equity-to-Asset is 0.68. BSF Enterprise's value of 0.51 is 25% below this industry median. Based on the distribution chart, BSF Enterprise ranks #932 out of 1414 companies in the Biotechnology industry, which is below the industry midpoint.
How does BSF Enterprise's Equity-to-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BSF Enterprise ranks #932 out of 1414 companies for Equity-to-Asset. This places BSF Enterprise in the lower half of its industry. The industry median Equity-to-Asset is 0.68. BSF Enterprise's value of 0.51 is 25% below this benchmark. Historically, BSF Enterprise's own Equity-to-Asset has ranged from 0.30 to 0.97 over the past decade. While the company's 10-year median is 0.91 vs. the industry median of 0.68, BSF Enterprise has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,414 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BSF Enterprise's current Equity-to-Asset of 0.51 is 25% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on BSF Enterprise and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BSF Enterprise's current Equity-to-Asset is 0.51, which is 44% below median its own 10-year median of 0.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BSF Enterprise stock overvalued right now?
BSF Enterprise (BSFAF) has a current Equity-to-Asset of 0.51. The current Equity-to-Asset is 0.51, which is 44% below median its 10-year median of 0.91 and 25% below the Biotechnology industry median of 0.68. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For BSF Enterprise (BSFAF), the current Equity-to-Asset is 0.51 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BSF Enterprise PLC is a United Kingdom-based biotech company. The Company is focused on developing biotechnological solutions using cell-based tissue engineering to help generate cultured meat, lab-grown leather, as well as human corneas, collagen growth and skin substitutes. The Company operates through its wholly owned subsidiary, 3D Bio-Tissues Limited (3DBT), which is a clinical and cellular agriculture company engaged in producing human corneas that could help restore vision to millions of people.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSFAF has been successfully added to your 
